Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 6Brain Neoplasms 4Breast Neoplasms 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 5Docetaxel 4ulixertinib 2Trastuzumab 2Radiotherapy 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Irinotecan 2Fluorodeoxyglucose F18 2Carboplatin 2Capecitabine 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1tanespimycin 1spartalizumab 1sonidegib 1sargramostim 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × NVP-BKM120 × CNS × Clear all
NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
120 enrolled
BreastCNSGastrointestinal

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡